No Data
No Data
No Data
No Data
No Data
News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
Dow JonesJun 2, 2023 05:08
Adaptimmune Completes Merger With Fellow Immunology Company TCR2
Seeking AlphaJun 2, 2023 05:02
Adaptimmune Announces Completion of Strategic Combination With TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 1, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced completion of an all-stock transaction in which Adaptimmune has combined with TCR2 Therapeutics Inc. (NASDAQ: TCRR) to create a preeminent T-cell therapy company to treat solid tumors.
newsfileJun 2, 2023 03:29
Shareholders of TCR2 Therapeutics (TCRR.US) increased their common stock holdings by 50,000 shares, worth about US$86,000
On May 31, it was reported that according to documents disclosed by the US Securities and Exchange Commission (SEC) on May 30, $TCR2 Therapeutics (TCRR.US) $shareholder TANG KEVIN C increased its common stock holdings at an average price of 1.72 US dollars per share on May 25, worth about 86,000 US dollars. The transaction involved other related parties: TANG CAPITAL MANAGEMENT LLC and TANG CAPITAL PARTNERS LP. Image source: SEC's official website What is a change in shareholding
Futu NewsMay 31, 2023 08:40
TCR2 Therapeutics Target Price Raised to $2.11 From $1.72 at Mizuho Securities
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Dow JonesMay 12, 2023 18:56
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in pe
BenzingaMay 11, 2023 21:25
No Data
No Data